Unlock tomorrow – be part of a passionate group working to make a difference
Celcuity is a commercial-stage biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid tumor indications. The company’s first FDA-approved product is REVTORPYK (gedatolisib), a potent, pan-PI3K and mTORC1/2 inhibitor that comprehensively blockades the PAM pathway. Multiple Phase 1b/2 and Phase 3 clinical trials evaluating gedatolisib in breast, prostate, and other solid tumor indications are ongoing.

